Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study

Contraception

Volumn 81, Issue 3, 2010, Pages 215-222

  Machado, Rogério Bonassi ^a   de Melo, Nilson Roberto ^b   Maia Jr , Hugo ^c  

^a Medicine School of Jundiaí   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Centro De Pesquisa E Assistencia Em Reproducao Humana   (Brazil)

Author keywords

Bleeding patterns; Continuous use; Drospirenone; Ethinylestradiol; Oral contraceptive

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL;

AMENORRHEA; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DYSMENORRHEA; EDEMA; FEMALE; HEADACHE; HORMONAL CONTRACEPTION; HUMAN; INCREASED APPETITE; MAJOR CLINICAL STUDY; MASTALGIA; MULTIPLE CYCLE TREATMENT; NAUSEA; PREMENSTRUAL SYNDROME; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT DURATION; UTERINE BLEEDING PATTERN;

ADULT; AMENORRHEA; ANALYSIS OF VARIANCE; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; DRUG ADMINISTRATION SCHEDULE; ETHINYL ESTRADIOL; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; LONGITUDINAL STUDIES; METRORRHAGIA; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; WOMEN'S HEALTH;

EID: 76049088778     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.10.010     Document Type: Article

References (20)

1. Nelson A.L. Extended-cycle oral contraception: a new option for routine use. Treat Endocrinol 4 (2005) 139-145
2. Edelman A., Gallo M.F., Nichols M.D., Jensen J.T., Schulz K.F., and Grimes D.A. Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials. Hum Reprod 21 (2006) 573-578
3. Sulak P.J., Kuehl T.J., Coffee A., and Willis S. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. Am J Obstet Gynecol 195 (2006) 935-941
4. den Tonkelaar I., and Oddens B.J. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 59 (1999) 357-362
5. Sulak P.J., Cressman B.E., Waldrop E., Holleman S., and Kuehl T.J. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 89 (1997) 179-183
6. Sulak P.J., Scow R.D., Preece C., Riggs M.W., and Kuehl T.J. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 95 (2000) 261-266
7. Anderson F.D., and Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 68 (2003) 89-96
8. Edelman A. Menstrual nirvana: amenorrhea through the use of continuous oral contraceptives. Curr Women's Health Rep 2 (2002) 434-438
9. Miller L., and Hughes J.P. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 101 (2003) 653-661
10. Kwiecien M., Edelman A., Nichols M.D., and Jensen J.T. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception 67 (2003) 9-13
11. Apter D., Borsos A., Baumgärtner W., et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 8 (2003) 37-51
12. Sillem M., Schneidereit R., Heithecker R., and Mueck A.O. Use of an oral contraceptive containing drospirenone in an extended regimen. Eur J Contracept Reprod Health Care 8 (2003) 162-169
13. Sulak P., Willis S., Kuehl T., Coffee A., and Clark J. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache 47 (2007) 27-37
14. Coffee A.L., Sulak P.J., and Kuehl T.J. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 75 (2007) 444-449
15. Edelman A.B., Koontz S.L., Nichols M.D., and Jensen J.T. Continuous oral contraceptives: are bleeding patterns dependent on the hormones given?. Obstet Gynecol 107 (2006) 657-665
16. Archer D.F., Jensen J.T., Johnson J.V., Borisute H., Grubb G.S., and Constantine G.D. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: Phase 3 study results. Contraception 74 (2006) 439-445
17. Machado R.B., Fabrini P., Cruz A.M., Maia E., and da Cunha Bastos A. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg). Contraception 70 (2004) 365-370
18. Foidart J.M., Wuttke W., Bouw G.M., Gerlinger C., and Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 5 (2000) 124-134
19. Huber J., Foidart J.M., Wuttke W., et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 5 (2000) 25-34
20. Parsey K.S., and Pong A. An open-label, multicenter study to evaluate Yasmin, a low- dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 61 (2000) 105-111